Tsubota Laboratory Inc
Tsubota Laboratory Inc is a Japanese company specializing in healthcare diagnostics, providing diagnostic reagents and related products for clinical and research applications.
Business. Tsubota Laboratory Inc (4890.T) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Japan and is primarily listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Tsubota Laboratory Inc (4890.T) is a healthcare diagnostics company operating within the biotechnology and medical research industry. The firm is headquartered in Japan and is primarily listed on the Tokyo Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Tsubota Laboratory Inc maintains a strong liquidity position, with cash and equivalents amounting to ¥1,538,853,000, representing 61.5% of total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, and its current ratio of 2.89 indicates a solid ability to meet short-term obligations. The debt-to-equity ratio of 0.06 suggests a conservative capital structure with minimal leverage.
Profitability metrics show a return on equity (ROE) of 12.96% and a return on assets (ROA) of 8.22%, both of which are strong indicators of efficient asset use and profitability. These figures are well above the industry median for Japanese healthcare diagnostics firms, suggesting Tsubota Laboratory Inc is outperforming its peers in terms of capital efficiency and earnings generation.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond Japan. This lack of geographic diversification may expose the company to regional economic or regulatory risks. No material revenue concentration by product or customer is reported, but the absence of segmental breakdowns limits visibility into potential vulnerabilities.
Tsubota Laboratory Inc has demonstrated consistent revenue growth, with a total revenue of ¥1,357,133,000 in the latest reporting period. While no forward-looking guidance is provided, the company's free cash flow of ¥220,526,000 and capital expenditure of ¥-13,994,000 suggest a stable and disciplined approach to capital allocation. The company's operating cash flow is negative, but this is offset by strong free cash flow generation, indicating that capital expenditures are being managed effectively.
Risk factors for Tsubota Laboratory Inc are currently low, with no immediate liquidity or dilution flags detected. The company's low debt load and strong cash position reduce financial risk exposure. However, the healthcare diagnostics industry is subject to regulatory changes and technological disruption, which could impact long-term performance. No dilution is expected in the near term, as shares outstanding remain unchanged between basic and diluted measures.
No recent filings or transcripts have been disclosed that would indicate material changes in the company's operations or strategy. The absence of recent events suggests a stable and predictable business environment for Tsubota Laboratory Inc.
- Tsubota Laboratory Inc maintains a strong liquidity position with a current ratio of 2.89 and a debt-to-equity ratio of 0.06.
- The company's ROE of 12.96% and ROA of 8.22% indicate strong profitability and efficient use of capital.
- Revenue is concentrated in a single business segment with no disclosed geographic diversification, increasing exposure to regional risks.
- Free cash flow of ¥220,526,000 and a negative operating cash flow suggest disciplined capital allocation and reinvestment.
- No immediate liquidity or dilution risks are present, but the healthcare diagnostics industry remains subject to regulatory and technological shifts.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Tsubota Laboratory Inc Market data — financials · 2026-05-26